January 15th, 2022
Chondrosarcoma Awareness Day is Sunday, February 6. As we approach this date we are posting inspirational stories about Chondrosarcoma Warriors defying the odds and winning their battle against this rare bone and soft tissue disease. As well as…
Read ArticleJanuary 10th, 2022
Chondrosarcoma Awareness Day is Sunday, February 6. As we approach this date we are posting inspirational stories about Chondrosarcoma Warriors defying the odds and winning their battle against this rare bone and soft tissue disease. As well as…
Read ArticleJanuary 5th, 2022
With the weeks leading up to Chondrosarcoma Awareness Day (February 6), we will be paying tribute to CS Patients that inspire us and continue their battle against this rare bone and soft tissue cancer as well as honoring and paying tribute to CS…
Read ArticleJanuary 4th, 2022
Targeting survivin as a potential new treatment for chondrosarcoma of bone
Y de Jong,
J G van Oosterwijk,
A B Kruisselbrink,
I H Briaire-de Bruijn,
G Agrogiannis,
Z Baranski,
A H G Cleven,
A-M Cleton-Jansen,
B van de Water,
E H J Danen &
J V…
Happy New Year!
Another new set of 8 teaching cases has been uploaded to the Johns Hopkins Bone and Soft Tissue Pathology Teaching Website (https://apps.pathology.jhu.edu/bone/). Please note that previous difficulties accessing…
Read ArticleDecember 31st, 2021
Our GoFundMe is still live! The CS Foundation is committed to improving the treatment of patients living with this rare bone & soft tissue cancer. We are currently raising money for the development of a Patient Registry & Natural History…
Read ArticleDecember 22nd, 2021
This is a website we have created geared for educational purposes in bone and soft tissue pathology. A new series of videos that have been uploaded to the site. Will be making multiple videos covering everything you could ever want to know about…
Read ArticleDecember 5th, 2021
– Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma
– Preliminary median progression-free survival (PFS) of 7.4 months and disease control rate of 89% observed in conventional chondrosarcoma…
